Applied Price To Sales Ratio vs Roic Analysis

APLT Stock

USD 9.63 0.36 3.88%

Applied Therapeutics financial indicator trend analysis is way more than just evaluating Applied Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Applied Therapeutics is a good investment. Please check the relationship between Applied Therapeutics Price To Sales Ratio and its Roic accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Applied Stock please use our How to Invest in Applied Therapeutics guide.

Price To Sales Ratio vs Roic

Price To Sales Ratio vs Roic Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Applied Therapeutics Price To Sales Ratio account and Roic. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Applied Therapeutics' Price To Sales Ratio and Roic is -0.41. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Roic in the same time period over historical financial statements of Applied Therapeutics, assuming nothing else is changed. The correlation between historical values of Applied Therapeutics' Price To Sales Ratio and Roic is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Applied Therapeutics are associated (or correlated) with its Roic. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Roic has no effect on the direction of Price To Sales Ratio i.e., Applied Therapeutics' Price To Sales Ratio and Roic go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Applied Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Applied Therapeutics sales, a figure that is much harder to manipulate than other Applied Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Most indicators from Applied Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Applied Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Applied Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Applied Stock please use our How to Invest in Applied Therapeutics guide.At this time, Applied Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 69.8 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 1.65 in 2024.

Applied Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Capital Lease Obligations	Property Plant And Equipment Gross	Net Receivables	Non Current Liabilities Other
Total Assets		0.54	0.61	0.75	0.89	-0.94	-0.66	0.52	0.96	1.0	0.49	-0.79	0.86	0.86	0.77	0.56	0.76	1.0	0.7	-0.59	-0.54	0.61	-0.55	-0.48	-0.27	-0.56
Other Current Liab	0.54		0.99	-0.14	0.79	-0.73	-0.94	0.05	0.65	0.54	1.0	-0.6	0.85	0.52	0.8	0.99	-0.13	0.54	-0.22	-0.89	-0.97	-0.23	-0.96	-0.97	-0.85	-0.7
Total Current Liabilities	0.61	0.99		-0.06	0.83	-0.77	-0.97	0.2	0.7	0.6	0.99	-0.67	0.89	0.64	0.83	1.0	-0.06	0.61	-0.15	-0.9	-0.98	-0.19	-0.97	-0.97	-0.84	-0.75
Total Stockholder Equity	0.75	-0.14	-0.06		0.42	-0.55	-0.03	0.51	0.62	0.76	-0.2	-0.47	0.35	0.57	0.28	-0.12	1.0	0.75	0.99	0.01	0.13	0.91	0.11	0.21	0.35	-0.08
Net Tangible Assets	0.89	0.79	0.83	0.42		-0.88	-0.88	0.38	0.87	0.88	0.75	-0.73	0.98	0.85	0.9	0.81	0.43	0.89	0.35	-0.83	-0.81	0.27	-0.81	-0.76	-0.63	-0.73
Net Debt	-0.94	-0.73	-0.77	-0.55	-0.88		0.78	-0.37	-0.99	-0.95	-0.69	0.8	-0.9	-0.75	-0.83	-0.73	-0.55	-0.94	-0.48	0.69	0.7	-0.45	0.7	0.66	0.4	0.61
Retained Earnings	-0.66	-0.94	-0.97	-0.03	-0.88	0.78		-0.3	-0.73	-0.65	-0.94	0.72	-0.94	-0.72	-0.93	-0.96	-0.04	-0.67	0.05	0.98	0.98	0.12	0.99	0.97	0.86	0.87
Accounts Payable	0.52	0.05	0.2	0.51	0.38	-0.37	-0.3		0.42	0.48	0.07	-0.6	0.4	0.77	0.39	0.14	0.51	0.52	0.46	-0.28	-0.17	0.22	-0.2	-0.15	-0.02	-0.5
Cash	0.96	0.65	0.7	0.62	0.87	-0.99	-0.73	0.42		0.96	0.61	-0.8	0.87	0.76	0.84	0.66	0.63	0.96	0.56	-0.66	-0.64	0.52	-0.64	-0.58	-0.34	-0.58
Cash And Short Term Investments	1.0	0.54	0.6	0.76	0.88	-0.95	-0.65	0.48	0.96		0.48	-0.77	0.85	0.83	0.76	0.55	0.76	1.0	0.7	-0.57	-0.53	0.63	-0.54	-0.46	-0.25	-0.53
Common Stock Shares Outstanding	0.49	1.0	0.99	-0.2	0.75	-0.69	-0.94	0.07	0.61	0.48		-0.57	0.82	0.51	0.77	0.99	-0.19	0.49	-0.28	-0.88	-0.97	-0.29	-0.96	-0.98	-0.86	-0.7
Non Current Liabilities Total	-0.79	-0.6	-0.67	-0.47	-0.73	0.8	0.72	-0.6	-0.8	-0.77	-0.57		-0.79	-0.85	-0.77	-0.61	-0.47	-0.79	-0.37	0.68	0.63	-0.17	0.64	0.6	0.51	0.63
Capital Surpluse	0.86	0.85	0.89	0.35	0.98	-0.9	-0.94	0.4	0.87	0.85	0.82	-0.79		0.85	0.94	0.86	0.35	0.86	0.27	-0.9	-0.88	0.18	-0.89	-0.84	-0.7	-0.82
Other Current Assets	0.86	0.52	0.64	0.57	0.85	-0.75	-0.72	0.77	0.76	0.83	0.51	-0.85	0.85		0.77	0.58	0.57	0.86	0.49	-0.67	-0.59	0.27	-0.61	-0.55	-0.45	-0.69
Other Stockholder Equity	0.77	0.8	0.83	0.28	0.9	-0.83	-0.93	0.39	0.84	0.76	0.77	-0.77	0.94	0.77		0.81	0.28	0.77	0.2	-0.95	-0.87	0.12	-0.88	-0.83	-0.73	-0.86
Total Liab	0.56	0.99	1.0	-0.12	0.81	-0.73	-0.96	0.14	0.66	0.55	0.99	-0.61	0.86	0.58	0.81		-0.11	0.56	-0.2	-0.89	-0.98	-0.23	-0.97	-0.98	-0.84	-0.73
Net Invested Capital	0.76	-0.13	-0.06	1.0	0.43	-0.55	-0.04	0.51	0.63	0.76	-0.19	-0.47	0.35	0.57	0.28	-0.11		0.76	0.99	0.0	0.12	0.91	0.1	0.2	0.34	-0.09
Total Current Assets	1.0	0.54	0.61	0.75	0.89	-0.94	-0.67	0.52	0.96	1.0	0.49	-0.79	0.86	0.86	0.77	0.56	0.76		0.69	-0.59	-0.54	0.61	-0.55	-0.48	-0.27	-0.56
Net Working Capital	0.7	-0.22	-0.15	0.99	0.35	-0.48	0.05	0.46	0.56	0.7	-0.28	-0.37	0.27	0.49	0.2	-0.2	0.99	0.69		0.09	0.21	0.94	0.19	0.29	0.43	-0.01
Short Long Term Debt Total	-0.59	-0.89	-0.9	0.01	-0.83	0.69	0.98	-0.28	-0.66	-0.57	-0.88	0.68	-0.9	-0.67	-0.95	-0.89	0.0	-0.59	0.09		0.96	0.16	0.97	0.94	0.89	0.91
Property Plant And Equipment Net	-0.54	-0.97	-0.98	0.13	-0.81	0.7	0.98	-0.17	-0.64	-0.53	-0.97	0.63	-0.88	-0.59	-0.87	-0.98	0.12	-0.54	0.21	0.96		0.25	1.0	1.0	0.9	0.84
Current Deferred Revenue	0.61	-0.23	-0.19	0.91	0.27	-0.45	0.12	0.22	0.52	0.63	-0.29	-0.17	0.18	0.27	0.12	-0.23	0.91	0.61	0.94	0.16	0.25		0.23	0.32	0.52	0.07
Capital Lease Obligations	-0.55	-0.96	-0.97	0.11	-0.81	0.7	0.99	-0.2	-0.64	-0.54	-0.96	0.64	-0.89	-0.61	-0.88	-0.97	0.1	-0.55	0.19	0.97	1.0	0.23		0.99	0.9	0.86
Property Plant And Equipment Gross	-0.48	-0.97	-0.97	0.21	-0.76	0.66	0.97	-0.15	-0.58	-0.46	-0.98	0.6	-0.84	-0.55	-0.83	-0.98	0.2	-0.48	0.29	0.94	1.0	0.32	0.99		0.91	0.82
Net Receivables	-0.27	-0.85	-0.84	0.35	-0.63	0.4	0.86	-0.02	-0.34	-0.25	-0.86	0.51	-0.7	-0.45	-0.73	-0.84	0.34	-0.27	0.43	0.89	0.9	0.52	0.9	0.91		0.71
Non Current Liabilities Other	-0.56	-0.7	-0.75	-0.08	-0.73	0.61	0.87	-0.5	-0.58	-0.53	-0.7	0.63	-0.82	-0.69	-0.86	-0.73	-0.09	-0.56	-0.01	0.91	0.84	0.07	0.86	0.82	0.71

Click cells to compare fundamentals

Applied Therapeutics Account Relationship Matchups

Applied Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	48.4M	104.5M	89.9M	38.4M	54.8M	56.5M
Other Current Liab	264K	19.8M	16.1M	27.9M	67.9M	71.3M
Total Current Liabilities	14.1M	21.2M	26.5M	33.4M	71.2M	74.7M
Total Stockholder Equity	32.6M	81.9M	62.5M	4.1M	(17.1M)	(16.3M)
Net Tangible Assets	(19.6M)	32.6M	81.9M	62.5M	71.9M	75.5M
Net Debt	(16.8M)	(55.7M)	(52.6M)	(15.8M)	(49.1M)	(46.7M)
Retained Earnings	(66.8M)	(160.7M)	(266.3M)	(348.8M)	(468.6M)	(445.2M)
Accounts Payable	8.8M	640K	9.5M	4.5M	1.7M	1.7M
Cash	18.9M	57.5M	53.9M	16.7M	49.9M	34.4M
Non Current Assets Total	2.2M	1.9M	1.5M	1.1M	447K	424.7K
Other Assets	199K	1.9M	200K	1.0	1.15	1.09
Cash And Short Term Investments	38.9M	96.8M	80.8M	30.6M	49.9M	50.1M
Common Stock Shares Outstanding	12.8M	22.0M	25.6M	37.8M	84.2M	88.5M
Liabilities And Stockholders Equity	48.4M	104.5M	89.9M	38.4M	54.8M	56.5M
Non Current Liabilities Total	1.7M	1.3M	891K	878K	797K	1.4M
Other Current Assets	7.3M	5.3M	7.0M	6.5M	4.2M	5.0M
Other Stockholder Equity	51.0M	242.8M	329.0M	352.8M	451.4M	230.2M
Total Liab	15.8M	22.6M	27.4M	34.3M	72.0M	75.6M
Net Invested Capital	32.6M	83.0M	63.3M	5.1M	(16.8M)	(16.0M)
Total Current Assets	46.2M	102.6M	88.4M	37.3M	54.4M	55.4M
Accumulated Other Comprehensive Income	(2K)	(112K)	(107K)	51K	45.9K	48.2K
Net Working Capital	32.1M	81.4M	61.9M	3.9M	(16.8M)	(16.0M)
Short Term Debt	356K	812K	884K	954K	858K	607.2K
Common Stock	1K	2K	3K	5K	8K	8.4K
Capital Stock	1K	2K	3K	5K	8K	8.4K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Applied Stock Analysis

When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC